SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Empliciti

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2015. No new regulatory filing or label expansion is imminent based on available information.
Why 3/10
Empliciti is an already-approved, marketed drug with no pending regulatory decision or pivotal readout scheduled in the next ~12 months. It contributes roughly $80-100 million in annual sales, a negligible fraction of BMY's ~$48B+ total revenue, and BMY is a diversified large-cap pharma. No binary catalyst exists to drive a material share-price move from this single product.
Actionable Insight NEUTRAL

Empliciti has no near-term binary catalysts. The next meaningful event to watch is the 2029-2030 patent expiry window, which could open the door to biosimilar competition, but that is several years away. For BMY investors, Empliciti is a non-factor; attention should be on the company's growth portfolio (Reblozyl, Breyanzi, Camzyos, Cobenfy) and the upcoming Eliquis patent cliff.

Price Chart

Loading chart...

Executive Summary

Empliciti (elotuzumab) is an FDA-approved monoclonal antibody for relapsed/refractory multiple myeloma, developed by Bristol Myers Squibb (BMY) in partnership with AbbVie. First approved in 2015 and expanded in 2018, it is a commercial-stage drug with roughly $80-100 million in annual sales -- a very small contributor to BMY's overall revenue. The drug faces intense competition from daratumumab (Darzalex, ~$6B+ market), CAR-T therapies, and bispecific antibodies. Key US composition-of-matter patent protection runs to 2029 (potentially 2030 with pediatric exclusivity). No upcoming regulatory catalysts or pivotal readouts are identified, making Empliciti a mature, low-impact product within BMY's broad portfolio.

How It Works

Empliciti is a monoclonal antibody (a lab-made immune protein) that targets a protein called SLAMF7 found on multiple myeloma cancer cells and on natural killer cells of the immune system. By binding to both, it helps the immune system recognize and destroy cancer cells. It is always used in combination with other drugs, never alone.

Trial Status

Empliciti was approved by the FDA in November 2015 based on the Phase 3 ELOQUENT-2 trial, which showed a 30% reduction in the risk of disease progression when combined with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who had received 1-3 prior therapies. A second approval in 2018 expanded use in combination with pomalidomide and dexamethasone (EPd) for patients who had received at least two prior therapies. A Phase 3 trial (ELOQUENT-1) testing Empliciti in newly diagnosed, untreated multiple myeloma failed to show a survival benefit. Two additional BMY-sponsored trials (NCT03651128, NCT02719613) involving elotuzumab have completed as of early 2026.

The Two-Sided Case

▲ Bull Case3
Empliciti remains a commercially viable option in the multiple myeloma treatment landscape with established combination regimens (ERd and EPd) and ongoing use in clinical practice.
The global elotuzumab market is projected to grow at a CAGR of roughly 7-8% through 2034, driven by rising multiple myeloma prevalence and demand for targeted cancer therapies.
Key US composition-of-matter patent protection extends to 2029-2030, providing a continued exclusivity runway with no near-term biosimilar threat.
▼ Bear Case4
Empliciti faces intense competition from far larger multiple myeloma therapies, particularly Johnson & Johnson's daratumumab (Darzalex, ~$6B+ in annual sales), which has broader label indications and subcutaneous formulation advantages.
Annual sales of roughly $80-100 million are immaterial to BMY's ~$48B+ total revenue, meaning the drug has essentially no impact on the company's financial performance or stock valuation.
A Phase 3 trial (ELOQUENT-1) failed to show benefit in newly diagnosed multiple myeloma, limiting label expansion potential, and the drug's use is confined to later-line relapsed/refractory settings.
Patent exclusivity ends around 2029-2030, exposing the franchise to eventual biosimilar competition without a clear pipeline replacement from this asset.

Upcoming Catalysts

  • No upcoming PDUFA dates, FDA Advisory Committee meetings, or pivotal Phase 3 readouts identified for Empliciti within the next 12 months.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 10

Hover a chip for the title
1 drugs.com2 news.bms.com3 drugpatentwatch.com4 en.wikipedia.org5 biospace.com6 pharmaphorum.com7 intelmarketresearch.com8 bms.com9 sec.gov10 sec.gov